全球電子臨床解決方案市場:按產品、交付方式、最終用戶、臨床試驗階段和地區劃分的未來預測(至 2027 年)
市場調查報告書
商品編碼
1210262

全球電子臨床解決方案市場:按產品、交付方式、最終用戶、臨床試驗階段和地區劃分的未來預測(至 2027 年)

eClinical Solutions Market by Product (CDMS, eCOA, CTMS, RTSM, ETMF, Analytics, Safety), Delivery (Web-hosted, Licensed Enterprise, Cloud-based), End User (Pharma, Hospitals, CROs), Clinical Trial Phases (Phase I, II) & Region - Global Forecasts to 2027

出版日期: | 出版商: MarketsandMarkets | 英文 293 Pages | 訂單完成後即時交付

價格
簡介目錄

全球電子臨床解決方案市場規模預計將從 2022 年的 96 億美元增長到 2027 年的 179 億美元,複合年增長率為 13.3%。

市場的主要驅動力是臨床研發的相關成本和監管要求不斷上升、政府的有利支持和資金、製藥和生物技術公司增加藥物開發的研發支出以及臨床研究,以及新軟件解決方案的滲透在

按交付方式,網絡託管(按需)模式領域將在 2021 年佔據最大的市場份額,達到 55.1%。 諸如易於用戶訪問、節省成本和快速檢索數據等好處是市場增長的主要驅動力。

按臨床試驗階段劃分,III 期臨床試驗部分將在 2021 年佔據最大份額,預計在預測期內將以最高複合年增長率增長。 關鍵驅動因素包括大量患者樣本人群的參與、臨床試驗的全球化以及對臨床試驗效率不斷增長的需求。

按最終用戶劃分,製藥和生物製藥公司將在 2021 年佔據最大份額,達到 38.5%。 這是由於臨床試驗期間臨床數據管理和分析軟件的使用增加以及確保先進醫療 IT 軟件的研發預算等因素所致。

按地區劃分,北美將在 2021 年佔據最大份額,而亞太地區預計將在 2022 年至 2027 年實現 16.3% 的最高複合年增長率。 主要製藥和生物製藥公司越來越多地外包臨床試驗、大量患者群體的存在以及進行臨床試驗的低成本等因素是推動亞太地區電子臨床解決方案市場增長的關鍵因素。

在本報告中,我們按產品、交付方式、臨床試驗階段分析了全球電子臨床解決方案(臨床試驗電子解決方案)市場、市場的基本結構和最新情況、驅動和製約市場的主要因素,我們是調查最終用戶和地區的市場趨勢前景、市場競爭狀況以及主要公司的概況。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 介紹
  • 市場動態
    • 司機
    • 約束因素
    • 機會
    • 任務
  • 臨床解決方案市場:生態系統分析
  • 案例研究
  • 價值鏈分析
  • 波特的五力分析
  • 監管狀況
  • 技術分析
  • 行業趨勢
    • 增加分散臨床試驗的數量
    • 遠程醫療的傳播和滲透
    • 醫療大數據的影響
  • 價格分析
  • 主要會議和活動 (2022-2023)
  • 主要利益相關者和採購標準

第 6 章電子臨床解決方案市場:按產品分類

  • 介紹
  • 電子數據採集 (EDC)/臨床數據管理系統 (CDMS)
  • 臨床試驗管理系統 (CTMS)
  • 臨床分析平台
  • 隨機化和研究供應管理 (RTSM) 系統
  • 臨床數據集成平台
  • 電子臨床結果評估 (eCOA) 解決方案
  • 安全解決方案
  • 電子臨床試驗文件 (eTMF) 系統
  • 電子許可解決方案
  • 監管信息管理系統
  • 其他電子臨床解決方案

第 7 章電子臨床解決方案市場:按交付方式

  • 介紹
  • 網絡主機型號
  • 持牌企業模式
  • 基於雲的解決方案

第 8 章電子臨床解決方案市場:按臨床試驗階段分類

  • 介紹
  • I 期臨床試驗
  • II 期臨床試驗
  • III 期臨床試驗
  • IV 期臨床試驗

第 9 章電子臨床解決方案市場:按最終用戶分類

  • 介紹
  • 製藥和生物製藥公司
  • CRO(合同研究組織)
  • 諮詢服務公司
  • 醫療設備製造商
  • 醫院
  • 教育和研究機構

第 10 章電子臨床解決方案市場:按地區

  • 介紹
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太國家
  • 其他國家(行)

第11章競爭格局

  • 介紹
  • 主要公司採用的策略
  • 主要公司的收入份額分析
  • 市場排名分析(2021 年)
  • 公司評估象限
  • 電子臨床解決方案市場:中小企業競爭評估象限
  • 競爭基準
  • 競爭形勢和趨勢
    • 推出產品和服務
    • 資本交易

第12章公司簡介

  • 主要公司
    • ORACLE CORPORATION
    • DASSAULT SYSTEMES
    • PAREXEL INTERNATIONAL CORPORATION
    • CLARIO
    • DATATRAK INT.
    • SIGNANT HEALTH (CRF HEALTH)
    • MAXISIT INC.
    • 4G CLINICAL
    • ECLINICAL SOLUTIONS LLC.
    • VEEVA SYSTEMS
  • 其他企業
    • RESEARCHMANAGER
    • SAAMA TECHNOLOGIES
    • MEDNET
    • ANJU SOFTWARE (PORTFOLIO COMPANY OF ABRY PARTNERS)
    • MEDRIO, INC.
    • CASTOR
    • CLINIPACE
    • IBM WATSON HEALTH
    • ARISGLOBAL
    • QURETEC LTD.
    • OPENCLINICA, LLC.
    • ADVARRA
    • REALTIME SOFTWARE SOLUTIONS, LLC
    • YPRIME LLC.
    • VIAL

第13章 附錄

簡介目錄
Product Code: HIT 2208

The global eClinical Solutions market is projected to reach USD 17.9 billion in 2027 from USD 9.6 billion in 2022 at a CAGR of 13.3%. Rising operational costs and regulatory requirements pertaining to clinical research studies, favorable government support & funding for clinical trials, increasing R&D expenditure on drug development by pharma-biotech companies and growing adoption of novel software solutions in clinical research are some of the major driving factors for the global eClinical solutions market.

Web-hosted (on-demand) models segment held the largest market share in 2021

Based on delivery mode, the global eClinical solutions market is segmented into web-hosted (on-demand), licensed enterprise (on-premises), and cloud-based (SaaS) models. In 2021, the web-hosted segment accounted for the largest share (55.1%) of the global eClinical solutions market. Advantages such as easy user access, reductions in cost, and faster retrieval of data are factors driving the market growth for web-hosted eClinical solutions during the forecast period.

Phase III clinical trials is expected to register the highest growth during the forecast period

Based on clinical trial phase, the eClinical solutions market has been segmented into phase I, II, III, and IV. The phase III clinical trials segment accounted for the largest share of the eClinical solutions market in 2021 and is expected to register the highest growth during the forecast period. The significant demand for eClinical solutions in phase III clinical trials is mainly attributed to the involvement of a large patient sample population size, the globalization of clinical trials, and the rising need to increase the efficiency of clinical trials.

Pharmaceutical & biopharmaceutical companies to dominate the eClinical solutions end user segment in 2021

Based on end user, the global eClinical solutions market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations, consultancy service companies, medical device manufacturers, hospitals, and academic & research institutes. The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of 38.5% of the global eClinical solutions market, by end user, in 2021. The large share of this segment can primarily be attributed to factors such as increasing applications of clinical data management and analytics software during clinical trials and the availability of R&D budgets for advanced healthcare IT software.

Asia Pacific to witness the highest growth between 2022 to 2027

In 2021, North America commanded the largest share of the eClinical solutions market, however, the Asia Pacific region is estimated to record the highest CAGR of 16.3% between 2022-2027. Increasing outsourcing of clinical trial studies by large pharmaceutical & biopharmaceutical companies, the presence of a large patient population, and low operating costs of conducting clinical trials are key factors driving the growth of the eClinical solutions market in the Asia Pacific region.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 33%, Tier 2 - 42%, and Tier 3 - 25% * By Designation: C-level - 29%, Director-level - 23%, and Others - 48% * By Region: North America - 35%, Europe - 30%, APAC -26%, Rest of the World -9%

The prominent players in this market include Oracle Corporation (US), Parexel International Corporation (US), Dassault Systemes (France), Clario (US), Datatrak International (US), Signant Health (US), 4G Clinical (US), MaxisIT (US), IBM Watson Health (US), eClinical Solutions LLC (US), Veeva Systems (US), Research Manager (US), Saama Technologies, LLC (US), Mednet (US), Anju Software, Inc (US), Medrio, Inc. (US), Castor (US), Clinipace (US), ArisGlobal (US), Quretec Ltd. (Estonia), OpenClinica, LLC (US), Advarra (US), RealTime Software Solutions, LLC (US), YPrime LLC. (US) and Vial (US).

Research Coverage

This report studies the eClinical Solutions market based on product, delivery mode, clinical trial phases, end users and region. It provides detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing the growth of this market and the factors impacting market dynamics. The report includes in-depth competitive analysis and the product matrix of the prominent players in this market, along with their company profiles, product portfolios, recent developments (mergers, acquisitions, partnerships, collaborations, etc.), and key business strategies. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments in different geographies.

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKET SEGMENTATION
    • 1.2.3 GEOGRAPHIES COVERED
    • 1.2.4 YEARS CONSIDERED
  • 1.3 CURRENCY CONSIDERED
  • 1.4 LIMITATIONS
  • 1.5 MAJOR MARKET STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
  • 2.2 RESEARCH METHODOLOGY STEPS
    • FIGURE 1 ECLINICAL SOLUTIONS MARKET: RESEARCH METHODOLOGY
  • 2.3 RESEARCH METHODOLOGY DESIGN
    • FIGURE 2 ECLINICAL SOLUTIONS MARKET: RESEARCH DESIGN
    • 2.3.1 SECONDARY DATA
      • 2.3.1.1 Secondary sources
    • 2.3.2 PRIMARY DATA
    • FIGURE 3 PRIMARY SOURCES
      • 2.3.2.1 Insights from primary experts
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
  • 2.4 MARKET SIZE ESTIMATION
    • FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
    • FIGURE 8 REVENUE ANALYSIS OF TOP 3 PUBLIC COMPANIES IN ECLINICAL SOLUTIONS MARKET (2021)
    • FIGURE 9 BOTTOM-UP APPROACH
    • FIGURE 10 ECLINICAL SOLUTIONS MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
    • FIGURE 11 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
    • FIGURE 12 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 1 ECLINICAL SOLUTIONS MARKET: RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ON ECLINICAL SOLUTIONS MARKET
    • TABLE 2 GLOBAL INFLATION RATE PROJECTION, 2021-2027 (% GROWTH)
    • TABLE 3 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 4 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 14 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 16 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 17 ECLINICAL SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 18 ECLINICAL SOLUTIONS MARKET: REGIONS COVERED (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 ECLINICAL SOLUTIONS MARKET OVERVIEW
    • FIGURE 19 INCREASING R&D EXPENDITURE ON DRUG DISCOVERY & DEVELOPMENT BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE & COUNTRY (2021)
    • FIGURE 20 WEB-HOSTED DELIVERY MODEL ACCOUNTED FOR LARGEST SHARE IN 2021
  • 4.3 GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 CHINA IS EXPECTED TO ACCOUNT FOR HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 ECLINICAL SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising operational costs and regulatory requirements associated with clinical research studies
      • 5.2.1.2 Growing adoption of novel software solutions in clinical research
      • 5.2.1.3 Favorable government support and funding for clinical trials
      • 5.2.1.4 Rising need for improved data standardization
      • 5.2.1.5 Increasing R&D expenditure on drug development by pharma-biotech companies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High implementation costs associated with eClinical solutions
      • 5.2.2.2 Shortage of skilled professionals
      • 5.2.2.3 Limited awareness among researchers
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing clinical trials in emerging countries
      • 5.2.3.2 Growing outsourcing of clinical trial processes to CROs
      • 5.2.3.3 Gradual shift from manual data interpretation to real-time data analysis
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited adoption in emerging countries due to budgetary constraints
      • 5.2.4.2 Concerns regarding software reliability
      • 5.2.4.3 Issues associated with patient privacy
  • 5.3 ECLINICAL SOLUTIONS MARKET: ECOSYSTEM ANALYSIS
    • FIGURE 23 ECOSYSTEM ANALYSIS
  • 5.4 CASE STUDIES
    • 5.4.1 YORK TEACHING HOSPITAL EXPEDITES DATA CAPTURE PROCESSING DURING PHASE III CLINICAL STUDY
    • 5.4.2 LSHTM AND MENAFRICAR INCORPORATE DATA CAPTURE SOFTWARE TO STUDY MENINGOCOCCAL CARRIAGE IN AFRICA
    • 5.4.3 CLINICAL TRIALS GROUP AT UCL UTILIZES EDC SYSTEM TO CAPTURE AND VERIFY PATIENT FEEDBACK
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 24 ECLINICAL SOLUTIONS MARKET: VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 HIGH CAPITAL INVESTMENTS TO RESTRICT ENTRY OF NEW PLAYERS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 THREAT OF SUBSTITUTES
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY LANDSCAPE
    • 5.7.1 NORTH AMERICA
    • 5.7.2 EUROPE
    • 5.7.3 ASIA PACIFIC
    • 5.7.4 MIDDLE EAST & AFRICA
    • 5.7.5 LATIN AMERICA
  • 5.8 TECHNOLOGY ANALYSIS
    • TABLE 6 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS
  • 5.9 INDUSTRY TRENDS
    • 5.9.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRAILS
    • 5.9.2 GROWING ADOPTION OF TELEMEDICINE
    • 5.9.3 IMPACT OF BIG DATA ON HEALTHCARE
  • 5.10 PRICING ANALYSIS
    • 5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS
    • TABLE 7 AVERAGE SELLING PRICE OF ECLINICAL SOLUTIONS, BY LICENSE
  • 5.11 KEY CONFERENCES AND EVENTS FROM 2022-2023
    • TABLE 8 ECLINICAL SOLUTIONS MARKET: LIST OF CONFERENCES AND EVENTS FROM 2022-2023
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS
    • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS AMONG END USERS
    • 5.12.1 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR END USERS
    • TABLE 10 KEY BUYING CRITERIA FOR END USERS

6 ECLINICAL SOLUTIONS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 11 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 12 ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
  • 6.2 ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS
    • 6.2.1 UTILIZATION OF COST-EFFECTIVE ECLINICAL SOLUTIONS INTEGRATED WITH EDC & CDM SYSTEMS TO DRIVE MARKET
    • TABLE 13 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 14 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 15 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 16 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 18 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 20 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC DATA CAPTURE & CLINICAL DATA MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 CLINICAL TRIAL MANAGEMENT SYSTEMS
    • 6.3.1 ABILITY TO BE DEPLOYED AS A SECURE WEB APPLICATION TO DRIVE UPTAKE
    • TABLE 21 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 22 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 23 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 24 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 26 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 28 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.4 CLINICAL ANALYTICS PLATFORMS
    • 6.4.1 ABILITY TO AUTOMATE CLINICAL DEVELOPMENT ACTIVITIES TO DRIVE MARKET
    • TABLE 29 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 30 ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 31 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 32 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 34 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL ANALYTICS PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS
    • 6.5.1 EFFECTIVE MANAGEMENT OF INVENTORY MONITORING AND RANDOMIZED PATIENT POOLS TO DRIVE ADOPTION
    • TABLE 37 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 38 ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 40 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 42 EUROPE: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR RANDOMIZATION & TRIAL SUPPLY MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.6 CLINICAL DATA INTEGRATION PLATFORMS
    • 6.6.1 ABILITY TO OPTIMIZE SECURE EXCHANGE OF EHR ON A USER-FRIENDLY GUI TO FUEL MARKET
    • TABLE 45 ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 46 ECLINICAL SOLUTIONS MARKET FOR CLINICAL TRIAL INTEGRATION PLATFORMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 48 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 50 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 52 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLINICAL DATA INTEGRATION PLATFORMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS
    • 6.7.1 INCREASING ADOPTION OF EPRO SOLUTIONS AND EDIARIES AMONG PHARMA COMPANIES TO DRIVE UPTAKE
    • TABLE 53 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 54 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 55 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 56 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 58 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.8 SAFETY SOLUTIONS
    • 6.8.1 ABILITY TO STREAMLINE SAFETY PROCESSING PROCESSES DURING CLINICAL TRIALS TO SUPPORT MARKET GROWTH
    • TABLE 61 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 62 ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 63 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 64 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 65 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 66 EUROPE: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 67 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR SAFETY SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.9 ELECTRONIC TRIAL MASTER FILE SYSTEMS
    • 6.9.1 RAPID SEARCH AND RETRIEVAL OF CLINICAL TRIAL DOCUMENTS WITH ETMF TO FUEL MARKET
    • TABLE 69 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 70 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 71 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 72 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 73 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 74 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC TRIAL MASTER FILE SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.10 ELECTRONIC CONSENT SOLUTIONS
    • 6.10.1 ABILITY TO ENSURE ADHERENCE TO ICF REGULATIONS TO INCREASE ADOPTION
    • TABLE 77 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 78 ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 79 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 80 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 81 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 82 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ELECTRONIC CONSENT SOLUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.11 REGULATORY INFORMATION MANAGEMENT SYSTEMS
    • 6.11.1 ABILITY TO ASSIST RESEARCHERS IN CENTRALIZING REGULATORY INFORMATION FOR OPTIMAL STANDARDIZATION TO DRIVE MARKET
    • TABLE 85 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 86 ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 87 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 88 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 89 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 90 EUROPE: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR REGULATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.12 OTHER ECLINICAL SOLUTIONS
    • TABLE 93 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 94 OTHER ECLINICAL SOLUTIONS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 95 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 96 NORTH AMERICA: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 97 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 98 EUROPE: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: OTHER ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE

  • 7.1 INTRODUCTION
    • TABLE 101 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 102 ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
  • 7.2 WEB-HOSTED MODELS
    • 7.2.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET
    • TABLE 103 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 104 ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 105 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 106 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTEL MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 107 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 108 EUROPE: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR WEB-HOSTED MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 LICENSED ENTERPRISE MODELS
    • 7.3.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE
    • TABLE 111 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 112 ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 113 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 114 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 115 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 116 EUROPE: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 117 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 118 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR LICENSED ENTERPRISE MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 CLOUD-BASED SOLUTIONS
    • 7.4.1 REMOTE CENTRALIZED ACCESS WITH REAL-TIME ANALYSIS TO DRIVE MARKET
    • TABLE 119 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 120 ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 121 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 122 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 123 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 124 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 126 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2020-2027 (USD MILLION)

8 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE

  • 8.1 INTRODUCTION
    • TABLE 127 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 128 ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
  • 8.2 PHASE I CLINICAL TRIALS
    • 8.2.1 ADOPTION OF EDC & CDM SYSTEMS IN PHASE I STUDIES TO DRIVE MARKET
    • TABLE 129 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 130 ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 131 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 132 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 133 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 134 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 136 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE I, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 PHASE II CLINICAL TRIALS
    • 8.3.1 UTILIZATION OF ECLINICAL SOLUTIONS IN STREAMLINING PHASE II TRIALS TO BOOST MARKET
    • TABLE 137 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 138 ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 139 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 140 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 141 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 142 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE II, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 PHASE III CLINICAL TRIALS
    • 8.4.1 INVOLVEMENT OF A LARGE PATIENT POPULATION TO DRIVE MARKET
    • TABLE 145 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 146 ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 147 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 148 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 149 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 150 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 151 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 152 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE III, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 PHASE IV CLINICAL TRIALS
    • 8.5.1 RISING DEMAND FOR POST-MARKETING SURVEILLANCE TO SUPPORT MARKET GROWTH
    • TABLE 153 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 154 ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 155 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 156 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 157 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 158 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 159 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 160 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHASE IV, BY COUNTRY, 2020-2027 (USD MILLION)

9 ECLINICAL SOLUTIONS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 161 ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 162 ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 9.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
    • TABLE 163 ECLINICAL SOLUTIONS MARKET SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 164 ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 165 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 166 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 167 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 168 EUROPE: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET
    • TABLE 171 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 172 ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 173 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 174 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR CROS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 175 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 176 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 177 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 178 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 CONSULTANCY SERVICE COMPANIES
    • 9.4.1 GROWING COLLABORATIONS FOR CDM BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET
    • TABLE 179 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 180 ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 181 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 182 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 183 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 184 EUROPE: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 185 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 186 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR CONSULTANCY SERVICE COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.5 MEDICAL DEVICE MANUFACTURERS
    • 9.5.1 UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL MARKET
    • TABLE 187 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 188 ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 189 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 190 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 191 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 192 EUROPE: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.6 HOSPITALS
    • 9.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET
    • TABLE 195 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 196 ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 197 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 198 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 199 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 200 EUROPE: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 202 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR HOSPITALS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.7 ACADEMIC & RESEARCH INSTITUTES
    • 9.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH
    • TABLE 203 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 204 ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 205 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 206 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 207 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 208 EUROPE: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 209 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 210 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)

10 ECLINICAL SOLUTIONS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 211 ECLINICAL SOLUTIONS MARKET, BY REGION, 2016-2019 (USD MILLION)
    • TABLE 212 ECLINICAL SOLUTIONS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET SNAPSHOT
    • TABLE 213 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 214 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 215 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 216 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 217 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 218 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 219 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 220 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 221 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 222 NORTH AMERICA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 Rising government funding for pharmaceutical R&D to drive market
    • FIGURE 28 DISTRIBUTION OF R&D COMPANIES BY COUNTRY/REGION (2021 VS. 2022)
    • TABLE 223 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 224 US: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 225 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 226 US: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 227 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 228 US: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 229 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 230 US: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
    • TABLE 231 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 232 CANADA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 233 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 234 CANADA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 235 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 236 CANADA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 237 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 238 CANADA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 239 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 240 EUROPE: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 241 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 242 EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 243 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 244 EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 245 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 246 EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 247 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 248 EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 High number of sponsored clinical trials to drive uptake of eClinical solutions
    • TABLE 249 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 250 GERMANY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 251 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 252 GERMANY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 253 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 254 GERMANY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 255 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 256 GERMANY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to boost market
    • TABLE 257 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 258 UK: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 259 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 260 UK: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 261 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 262 UK: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 263 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 264 UK: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Growing R&D pipeline for oncology trials to drive market
    • TABLE 265 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 266 FRANCE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 267 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 268 FRANCE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 269 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 270 FRANCE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 271 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 272 FRANCE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake
    • TABLE 273 NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022)
    • TABLE 274 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 275 ITALY: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 276 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 277 ITALY: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 278 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 279 ITALY: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 280 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 281 ITALY: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Established network of research centers to propel market
    • TABLE 282 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 283 SPAIN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 284 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 285 SPAIN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 286 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 287 SPAIN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 288 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 289 SPAIN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 290 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 291 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 292 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 293 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 294 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 295 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 296 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 297 REST OF EUROPE: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 29 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET SNAPSHOT
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 298 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2016-2019 (USD MILLION)
    • TABLE 299 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 300 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 301 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 302 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 303 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 304 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 305 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 306 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 307 ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market
    • TABLE 308 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 309 CHINA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 310 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 311 CHINA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 312 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 313 CHINA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 314 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 315 CHINA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Established clinical trial infrastructure and biomedical research capabilities to support market growth
    • TABLE 316 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 317 JAPAN: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 318 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 319 JAPAN: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 320 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 321 JAPAN: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 322 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 323 JAPAN: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Growing pharmaceutical industry to fuel uptake of eClinical solutions
    • TABLE 324 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 325 INDIA: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 326 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 327 INDIA: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 328 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 329 INDIA: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 330 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 331 INDIA: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 332 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 333 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 334 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 335 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 336 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 337 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 338 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 339 REST OF ASIA PACIFIC: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 340 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2016-2019 (USD MILLION)
    • TABLE 341 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 342 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2016-2019 (USD MILLION)
    • TABLE 343 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY DELIVERY MODE, 2020-2027 (USD MILLION)
    • TABLE 344 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2016-2019 (USD MILLION)
    • TABLE 345 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)
    • TABLE 346 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER, 2016-2019 (USD MILLION)
    • TABLE 347 REST OF THE WORLD: ECLINICAL SOLUTIONS MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.5.1 REST OF THE WORLD: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
    • FIGURE 30 ECLINICAL SOLUTIONS MARKET: KEY PLAYERS
  • 11.4 MARKET RANKING ANALYSIS (2021)
    • FIGURE 31 ECLINICAL SOLUTIONS MARKET: COMPANY RANKS (2021)
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 32 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021)
  • 11.6 ECLINICAL SOLUTIONS MARKET: COMPETITIVE EVALUATION QUADRANT FOR SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 33 ECLINICAL SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT FOR SMES (2021)
  • 11.7 COMPETITIVE BENCHMARKING
    • FIGURE 34 ECLINICAL SOLUTIONS MARKET: OVERALL FOOTPRINT OF 15 COMPANIES
    • TABLE 348 ECLINICAL SOLUTIONS MARKET: COMPANY PRODUCT FOOTPRINT
    • TABLE 349 ECLINICAL SOLUTIONS MARKET: END USER FOOTPRINT
    • TABLE 350 ECLINICAL SOLUTIONS MARKET: COMPANY REGIONAL FOOTPRINT
  • 11.8 COMPETITIVE SITUATIONS AND TRENDS
    • 11.8.1 PRODUCT AND SERVICE LAUNCHES
    • TABLE 351 PRODUCT AND SERVICE LAUNCHES (2019-2022)
    • 11.8.2 DEALS
    • TABLE 352 DEALS (2019-2022)

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 ORACLE CORPORATION
    • TABLE 353 ORACLE CORPORATION: BUSINESS OVERVIEW
    • FIGURE 35 ORACLE CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.2 DASSAULT SYSTEMES
    • TABLE 354 DASSAULT SYSTEMES: BUSINESS OVERVIEW
    • FIGURE 36 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2021)
    • 12.1.3 PAREXEL INTERNATIONAL CORPORATION
    • TABLE 355 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW
    • 12.1.4 CLARIO
    • TABLE 356 CLARIO: BUSINESS OVERVIEW
    • 12.1.5 DATATRAK INT.
    • TABLE 357 DATATRAK INT.: BUSINESS OVERVIEW
    • FIGURE 37 DATATRAK INT.: COMPANY SNAPSHOT (2021)
    • 12.1.6 SIGNANT HEALTH (CRF HEALTH)
    • TABLE 358 SIGNANT HEALTH: BUSINESS OVERVIEW
    • 12.1.7 MAXISIT INC.
    • TABLE 359 MAXISIT INC.: BUSINESS OVERVIEW
    • 12.1.8 4G CLINICAL
    • TABLE 360 4G CLINICAL: BUSINESS OVERVIEW
    • 12.1.9 ECLINICAL SOLUTIONS LLC.
    • TABLE 361 ECLINICAL SOLUTIONS: BUSINESS OVERVIEW
    • 12.1.10 VEEVA SYSTEMS
    • TABLE 362 VEEVA SYSTEMS: BUSINESS OVERVIEW
    • FIGURE 38 VEEVA SYSTEMS: COMPANY SNAPSHOT (2021)
  • 12.2 OTHER PLAYERS
    • 12.2.1 RESEARCHMANAGER
    • 12.2.2 SAAMA TECHNOLOGIES
    • 12.2.3 MEDNET
    • 12.2.4 ANJU SOFTWARE (PORTFOLIO COMPANY OF ABRY PARTNERS)
    • 12.2.5 MEDRIO, INC.
    • 12.2.6 CASTOR
    • 12.2.7 CLINIPACE
    • 12.2.8 IBM WATSON HEALTH
    • 12.2.9 ARISGLOBAL
    • 12.2.10 QURETEC LTD.
    • 12.2.11 OPENCLINICA, LLC.
    • 12.2.12 ADVARRA
    • 12.2.13 REALTIME SOFTWARE SOLUTIONS, LLC
    • 12.2.14 YPRIME LLC.
    • 12.2.15 VIAL
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS